# Lyndell L. Lim

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lyndell-l-lim/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,057 |
| Field | Ocular Diseases and Behçet’s Syndrome |
| h-index | 41 |
| i10-index | 98 |
| Last Known Institution | The Royal Melbourne Hospital |
| OpenAlex ID | https://openalex.org/A5070294227 |
| ORCID iD | 0000-0003-2491-685X |
| Works | 271 |

## Researcher papers

- [The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and Australia](https://scholariq.org/papers/the-prevalence-of-retinal-vein-occlusion-pooled-data-from-population-studies/)
- [Natural History of Central Retinal Vein Occlusion: An Evidence-Based Systematic Review](https://scholariq.org/papers/natural-history-of-central-retinal-vein-occlusion-an-evidence-based-systematic/)
- [Natural History of Branch Retinal Vein Occlusion: An Evidence-Based Systematic Review](https://scholariq.org/papers/natural-history-of-branch-retinal-vein-occlusion-an-evidence-based-systematic/)
- [Do tumor necrosis factor inhibitors cause uveitis? A registry‐based study](https://scholariq.org/papers/do-tumor-necrosis-factor-inhibitors-cause-uveitis-a-registry-based-study/)
- [Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen](https://scholariq.org/papers/tolerating-subretinal-fluid-in-neovascular-age-related-macular-degeneration/)
- [A Randomized Clinical Trial of Intravitreal Bevacizumab versus Intravitreal Dexamethasone for Diabetic Macular Edema](https://scholariq.org/papers/a-randomized-clinical-trial-of-intravitreal-bevacizumab-versus-intravitreal/)
- [Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis](https://scholariq.org/papers/guidance-on-noncorticosteroid-systemic-immunomodulatory-therapy-in-noninfectious/)
- [Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III](https://scholariq.org/papers/safety-and-efficacy-of-adalimumab-in-patients-with-noninfectious-uveitis-in-an/)
- [Two-Year Outcomes of “Treat and Extend” Intravitreal Therapy for Neovascular Age-Related Macular Degeneration](https://scholariq.org/papers/two-year-outcomes-of-treat-and-extend-intravitreal-therapy-for-neovascular-age/)
- [Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 18-Month Results of the Phase 3 GALILEO Study](https://scholariq.org/papers/intravitreal-aflibercept-for-macular-edema-secondary-to-central-retinal-vein/)
- [A systemic review of the utility of antituberculosis therapy for presumed tuberculous uveitis](https://scholariq.org/papers/a-systemic-review-of-the-utility-of-antituberculosis-therapy-for-presumed/)

## Researcher topics

- [Ocular Diseases and Behçet’s Syndrome](https://scholariq.org/topics/ocular-diseases-and-behcet-s-syndrome/)
- [Retinal Diseases and Treatments](https://scholariq.org/topics/retinal-diseases-and-treatments/)
- [Retinal and Optic Conditions](https://scholariq.org/topics/retinal-and-optic-conditions/)
- [Retinal Imaging and Analysis](https://scholariq.org/topics/retinal-imaging-and-analysis/)
- [Sarcoidosis and Beryllium Toxicity Research](https://scholariq.org/topics/sarcoidosis-and-beryllium-toxicity-research/)

## Researcher university

- [The Royal Melbourne Hospital](https://scholariq.org/institutions/the-royal-melbourne-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.